spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Myasthenia Gravis 

 HSMN NewsFeed - 21 Oct 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2024
HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2024
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar(R) Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 19 Jan 2024
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 13 Dec 2023
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2022
COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2021
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2020
Chord Therapeutics launches with USD 16 million Series A financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Oct 2020
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 19 Aug 2020
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2018
Geoffrey B. Davis Joins GT Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Oct 2017
Mylan Launches First AP-rated Generic Avelox(R) Injection
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2015
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2015
Impax Receives FDA Approval for Generic Version of Mestinon(R) Timespan(R) Tablets, 180 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Aug 2014
European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 Oct 2012
Gliknik Raises $4.9 Million In Series B Financing Led By Baxter Ventures
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 21 Jul 2011
Merz Aesthetics Announces FDA Approval Of XEOMIN(R) (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2009
Amarin Appoints John F. Thero as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2009
Amarin Announces Changes to Its Board and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2009
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Sep 2008
Amarin Appoints Dr. Paresh Soni as SVP and Head of Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2008
Allergan Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2008
Meda Acquires European Businesses from American Valeant and Enters the Russian Market
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Dec 2007
Amarin Announces Management Changes Including Appointment of New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2007
Amarin Signs Agreement to Acquire Ester Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 8 Oct 2007
Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Jul 2007
Aspreva announces restructuring designed to drive long-term growth
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jan 2007
Allergan, Inc. Announces Nationwide Availability of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS Dermal Fillers
Devices
 HSMN NewsFeed - 29 Dec 2006
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
Biopharmaceuticals Generics
 HSMN NewsFeed - 17 Nov 2006
Neuro-Hitech Announces Agreement to Acquire Q-RNA, Inc.
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2006
Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Oct 2006
Important safety information about KETEK (telithromycin)
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2006
Mutual Pharmaceutical Company/AR Scientific Launches QUALAQUIN(TM) (quinine sulfate capsules USP, 324 mg)
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Myasthenia Gravis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.